MDxHealth S.A.(MDXH)Earnings, Financials & Key Ratios
MDXH•NASDAQ
Price updated Jun 24, 2026
AboutMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Show more
- Revenue$108M+19.8%
- EBITDA-$6M+62.9%
- Net Income-$34M+12.0%
- EPS (Diluted)-0.67+42.2%
- Gross Margin59.74%-2.4%
- EBITDA Margin-5.74%+69.0%
- Operating Margin-14.28%+48.0%
- Net Margin-31.07%+26.5%
- ROE-2440.41%-606.7%
MDXH Key Insights
MDxHealth S.A. (MDXH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 42.3%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MDXH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDXH Price & Volume
MDxHealth S.A. (MDXH) stock price & volume — 10-year historical chart
Loading chart...
MDXH Growth Metrics
MDxHealth S.A. (MDXH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.97%
5 Years42.34%
3 Years42.79%
TTM59.74%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM67.22%
Return on Capital
10 Years-50.66%
5 Years-35.86%
3 Years-20.82%
Last Year-14.46%
MDXH Recent Earnings
MDxHealth S.A. (MDXH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.19-31.4%
$0.14
Rev
$24M-22.6%
$31M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.17-30.8%
$0.13
Rev
$30M-2.7%
$30M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.16-33.3%
$0.12
Rev
$53M+103.2%
$26M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.15-15.4%
$0.13
Rev
$27M+1.1%
$26M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.19vs $0.14-31.4% | $24Mvs $31M-22.6% |
| Q1 2026 | Feb 26, 2026 | $0.17vs $0.13-30.8% | $30Mvs $30M-2.7% |
| Q4 2025 | Nov 12, 2025 | $0.16vs $0.12-33.3% | $53Mvs $26M+103.2% |
| Q3 2025 | Aug 5, 2025 | $0.15vs $0.13-15.4% | $27Mvs $26M+1.1% |
Based on last 12 quarters of dataView full earnings history →
MDXH Peer Comparison
MDxHealth S.A. (MDXH) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 4.53B | 56.76 | 69.22 | 16.01% | 16.25% | 6.86% | 0.03 | |
 NTRA | 37.23B | 259.97 | -171.03 | 35.9% | -9.05% | -15.13% | 0.13 | |
 QDEL | 831.28M | 12.21 | -0.73 | -1.89% | -45.57% | -56.31% | 1.46 | |
 ILMN | 26.6B | 175.09 | 32.13 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 447.27M | 1.44 | -0.79 | 3.89% | -80.34% | -488.45% | 141.98 | |
 CDNA | 1.4B | 27.13 | -67.83 | 13.79% | -1.98% | -2.61% | 0.06 | |
 PRME | 563.53M | 3.12 | -2.31 | 55.28% | -49.18% | -188.82% | 0.96 |
Compare MDXH vs Peers
MDxHealth S.A. (MDXH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDXH Income Statement
MDxHealth S.A. (MDXH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 40.51M | 28.34M | 11.79M | 18.46M | 22.24M | 37.05M | 70.19M | 90.05M | 107.88M |
Revenue Growth % | 35.63% | -30.04% | -58.41% | 56.64% | 20.47% | 66.62% | 89.43% | 28.29% | 19.8% |
Cost of Goods Sold | 10.2M | 11.65M | 11.93M | 10.42M | 11.68M | 17.84M | 26.26M | 34.91M | 43.43M |
COGS % of Revenue | 25.19% | 41.12% | 101.22% | 56.42% | 52.5% | 48.13% | 37.42% | 38.77% | 40.26% |
Gross Profit | 30.3M▲ 0% | 16.69M▼ 44.9% | -144K▼ 100.9% | 8.04M▲ 5686.1% | 10.56M▲ 31.3% | 19.22M▲ 81.9% | 43.93M▲ 128.6% | 55.14M▲ 25.5% | 64.44M▲ 16.9% |
Gross Margin % | 74.81% | 58.88% | -1.22% | 43.58% | 47.5% | 51.87% | 62.58% | 61.23% | 59.74% |
Gross Profit Growth % | 53.33% | -44.94% | -100.86% | 5686.11% | 31.33% | 81.93% | 128.57% | 25.52% | 16.87% |
Operating Expenses | 42.58M | 48.78M | 43.02M | 35.17M | 37.41M | 57.12M | 71.26M | 79.86M | 79.84M |
OpEx % of Revenue | 105.11% | 172.15% | 365.08% | 190.5% | 168.2% | 154.15% | 101.51% | 88.69% | 74.01% |
Selling, General & Admin | 13.51M | 15.26M | 10.1M | 28.61M | 30.22M | 50.12M | 59.92M | 61.4M | 66.75M |
SG&A % of Revenue | 33.34% | 53.85% | 85.74% | 155% | 135.87% | 135.26% | 85.37% | 68.18% | 61.88% |
Research & Development | 1.83M | 1.81M | 9M | 4.54M | 5.59M | 7.56M | 6.38M | 10.55M | 10.35M |
R&D % of Revenue | 4.51% | 6.39% | 76.34% | 24.61% | 25.13% | 20.39% | 9.08% | 11.72% | 9.59% |
Other Operating Expenses | 27.25M | 31.71M | 23.92M | 2.01M | 1.6M | -559K | 4.96M | 7.92M | 2.74M |
Operating Income | -12.27M▲ 0% | -32.1M▼ 161.5% | -43.17M▼ 34.5% | -27.12M▲ 37.2% | -26.84M▲ 1.0% | -37.9M▼ 41.2% | -27.33M▲ 27.9% | -24.72M▲ 9.5% | -15.4M▲ 37.7% |
Operating Margin % | -30.3% | -113.27% | -366.3% | -146.93% | -120.69% | -102.28% | -38.93% | -27.45% | -14.28% |
Operating Income Growth % | 4.45% | -161.51% | -34.49% | 37.17% | 1.04% | -41.2% | 27.9% | 9.53% | 37.7% |
EBITDA | -10.06M | -29.16M | -39.75M | -23.79M | -23.8M | -32.99M | -20.47M | -16.68M | -6.19M |
EBITDA Margin % | -24.83% | -102.9% | -337.28% | -128.88% | -107.04% | -89.03% | -29.16% | -18.53% | -5.74% |
EBITDA Growth % | 9.58% | -189.87% | -36.31% | 40.15% | -0.06% | -38.59% | 37.96% | 18.49% | 62.88% |
D&A (Non-Cash Add-back) | 2.21M | 2.94M | 3.42M | 3.33M | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
EBIT | -12.4M | -32.41M | -43.16M | -27.31M | -27.13M | -41.3M | -37.33M | -30.06M | -15.4M |
Net Interest Income | -122K | -61K | -506K | -1.54M | -1.87M | -2.62M | -4.68M | -6.55M | -10.66M |
Interest Income | 0 | 21K | 10K | 4K | 11K | 125K | 1.09M | 1.08M | 1.5M |
Interest Expense | 122K | 82K | 516K | 1.54M | 1.88M | 2.74M | 5.77M | 7.63M | 12.16M |
Other Income/Expense | -127K | -393K | -506K | -1.54M | -2.16M | -6.14M | -15.77M | -12.96M | -19.98M |
Pretax Income | -12.4M▲ 0% | -32.49M▼ 162.0% | -43.67M▼ 34.4% | -28.66M▲ 34.4% | -29M▼ 1.2% | -44.04M▼ 51.9% | -43.1M▲ 2.1% | -37.69M▲ 12.6% | -35.38M▲ 6.1% |
Pretax Margin % | -30.61% | -114.66% | -370.6% | -155.27% | -130.41% | -118.86% | -61.4% | -41.85% | -32.79% |
Income Tax | -113K | -41K | -575K | 0 | 0 | 0 | 1K | 382K | -1.86M |
Effective Tax Rate % | 0.91% | 0.13% | 1.32% | 0% | 0% | 0% | -0% | -1.01% | 5.25% |
Net Income | -12.29M▲ 0% | -32.45M▼ 164.1% | -43.1M▼ 32.8% | -28.66M▲ 33.5% | -29M▼ 1.2% | -44.04M▼ 51.9% | -43.1M▲ 2.1% | -38.07M▲ 11.7% | -33.52M▲ 12.0% |
Net Margin % | -30.33% | -114.51% | -365.72% | -155.27% | -130.41% | -118.86% | -61.4% | -42.28% | -31.07% |
Net Income Growth % | 6.73% | -164.08% | -32.82% | 33.5% | -1.19% | -51.87% | 2.14% | 11.67% | 11.95% |
Net Income (Continuing) | -12.29M | -32.45M | -43.1M | -28.66M | -29M | -44.04M | -43.1M | -38.07M | -33.52M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.46▲ 0% | -5.63▼ 128.9% | -6.89▼ 22.4% | -3.44▲ 50.1% | -2.38▲ 30.8% | -2.78▼ 16.8% | -1.66▲ 40.3% | -1.16▲ 30.1% | -0.67▲ 42.2% |
EPS Growth % | 13.99% | -128.86% | -22.38% | 50.07% | 30.81% | -16.81% | 40.29% | 30.12% | 42.24% |
EPS (Basic) | -2.46 | -5.63 | -6.89 | -3.44 | -2.38 | -2.78 | -1.66 | -0.78 | -0.67 |
Diluted Shares Outstanding | 4.99M | 5.76M | 6.26M | 8.32M | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
Basic Shares Outstanding | 4.99M | 5.76M | 6.26M | 8.32M | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MDXH Balance Sheet
MDxHealth S.A. (MDXH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 39.32M | 47.86M | 30.91M | 23.09M | 66.61M | 29.15M | 38.16M | 66.89M | 53.41M |
Cash & Short-Term Investments | 16.83M | 26.2M | 22.1M | 15.95M | 58.59M | 15.6M | 22.38M | 46.8M | 29.03M |
Cash Only | 16.83M | 26.2M | 22.05M | 15.95M | 58.5M | 15.5M | 22.38M | 46.8M | 29.03M |
Short-Term Investments | 0 | 0 | 51K | 0 | 89K | 101K | 0 | 0 | 0 |
Accounts Receivable | 19.93M | 19.13M | 6.64M | 3.89M | 4.58M | 9.36M | 11.27M | 14.53M | 14.68M |
Days Sales Outstanding | 179.59 | 246.42 | 205.81 | 76.99 | 75.2 | 92.17 | 58.61 | 58.9 | 49.65 |
Inventory | 1.92M | 1.81M | 1.19M | 2.32M | 1.91M | 2.33M | 2.78M | 3.87M | 6.74M |
Days Inventory Outstanding | 68.65 | 56.6 | 36.47 | 81.44 | 59.74 | 47.62 | 38.62 | 40.45 | 56.65 |
Other Current Assets | 24K | 104K | 54K | 52K | 504K | 151K | 146K | 135K | 2.96M |
Total Non-Current Assets | 19.2M | 17.61M | 9.72M | 8.77M | 8.47M | 89.99M | 90.97M | 90.43M | 94.54M |
Property, Plant & Equipment | 2.57M | 2.07M | 2.45M | 3.71M | 5.02M | 7.89M | 9.95M | 12.98M | 14.68M |
Fixed Asset Turnover | 15.77x | 13.66x | 4.81x | 4.98x | 4.43x | 4.69x | 7.06x | 6.94x | 7.35x |
Goodwill | 1.15M | 1.15M | 0 | 0 | 0 | 35.93M | 35.93M | 35.93M | 38.95M |
Intangible Assets | 15.49M | 14.39M | 7.27M | 5.06M | 3.45M | 46.17M | 44.34M | 40.59M | 39.42M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 763K | 936K | 1.5M |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Total Assets | 58.52M▲ 0% | 65.48M▲ 11.9% | 40.63M▼ 37.9% | 31.86M▼ 21.6% | 75.07M▲ 135.7% | 119.14M▲ 58.7% | 129.13M▲ 8.4% | 157.33M▲ 21.8% | 147.95M▼ 6.0% |
Asset Turnover | 0.69x | 0.43x | 0.29x | 0.58x | 0.30x | 0.31x | 0.54x | 0.57x | 0.73x |
Asset Growth % | -13.59% | 11.88% | -37.95% | -21.59% | 135.66% | 58.69% | 8.39% | 21.84% | -5.96% |
Total Current Liabilities | 13.12M | 11.48M | 10.43M | 13.02M | 16.43M | 18.28M | 19.52M | 42.66M | 49.53M |
Accounts Payable | 8.05M | 6.45M | 4.96M | 5.32M | 7.46M | 10.18M | 8.81M | 8M | 10.33M |
Days Payables Outstanding | 288.16 | 202.14 | 151.7 | 186.42 | 233.07 | 208.3 | 122.45 | 83.66 | 86.81 |
Short-Term Debt | 191K | 147K | 565K | 2.82M | 4.44M | 616K | 643K | 324K | 1.9M |
Deferred Revenue (Current) | 3.82M | 4.36M | 0 | 3.22M | 0 | 0 | 472K | 0 | 0 |
Other Current Liabilities | 883K | 402K | 909K | -2.31M | 961K | 2.33M | 2.9M | 26.41M | 37.31M |
Current Ratio | 3.00x | 4.17x | 2.96x | 1.77x | 4.05x | 1.59x | 1.95x | 1.57x | 1.08x |
Quick Ratio | 2.85x | 4.01x | 2.85x | 1.59x | 3.94x | 1.47x | 1.81x | 1.48x | 0.94x |
Cash Conversion Cycle | -39.92 | 100.89 | 90.58 | -27.99 | -98.12 | -68.5 | -25.22 | 15.7 | 19.49 |
Total Non-Current Liabilities | 1.86M | 1.88M | 10.48M | 12.99M | 11.74M | 91.54M | 102.4M | 99.83M | 110.51M |
Long-Term Debt | 147K | 0 | 9.05M | 10.28M | 7.65M | 34.91M | 35.56M | 50.97M | 84.71M |
Capital Lease Obligations | 376K | 262K | 735K | 2.02M | 2.62M | 3.09M | 3.58M | 7.41M | 8.51M |
Deferred Tax Liabilities | 616K | 575K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 661K | 1.04M | 690K | 690K | 1.47M | 53.54M | 63.26M | 41.45M | 17.3M |
Total Liabilities | 14.97M | 13.36M | 20.9M | 26.01M | 28.17M | 109.82M | 121.92M | 142.49M | 160.05M |
Total Debt | 884K | 526K | 11M | 15.87M | 15.56M | 39.79M | 41.27M | 60.06M | 95.11M |
Net Debt | -15.94M | -25.68M | -11.05M | -82K | -42.94M | 24.29M | 18.89M | 13.27M | 66.08M |
Debt / Equity | 0.02x | 0.01x | 0.56x | 2.71x | 0.33x | 4.27x | 5.72x | 4.05x | - |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | -101.65x | -395.23x | -83.64x | -17.70x | -14.47x | -15.06x | -6.47x | -3.94x | -1.27x |
Total Equity | 43.55M▲ 0% | 52.12M▲ 19.7% | 19.72M▼ 62.2% | 5.85M▼ 70.3% | 46.9M▲ 701.8% | 9.31M▼ 80.1% | 7.21M▼ 22.6% | 14.84M▲ 105.9% | -12.09M▼ 181.5% |
Equity Growth % | -17.43% | 19.68% | -62.15% | -70.35% | 701.83% | -80.14% | -22.62% | 105.9% | -181.49% |
Book Value per Share | 8.72 | 9.05 | 3.15 | 0.70 | 3.85 | 0.59 | 0.28 | 0.30 | -0.24 |
Total Shareholders' Equity | 43.55M | 52.12M | 19.72M | 5.85M | 46.9M | 9.31M | 7.21M | 14.84M | -12.09M |
Common Stock | 45.95M | 53.88M | 70.72M | 76.72M | 143.42M | 148.42M | 173.93M | 214.67M | 219.21M |
Retained Earnings | -111.09M | -143.54M | -186.64M | -215.3M | -244.3M | -288.35M | -331.45M | -369.51M | -403.03M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 1.24M | -1.17M | -704K | 8.08M | -5.39M | -3.94M | 11.55M | -615K | 18.55M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDXH Cash Flow Statement
MDxHealth S.A. (MDXH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.49M | -28.54M | -22.29M | -20.24M | -22.55M | -34.12M | -21.5M | -18.53M | -10.42M |
Operating CF Margin % | -25.89% | -100.72% | -189.13% | -109.66% | -101.39% | -92.08% | -30.63% | -20.58% | -9.66% |
Operating CF Growth % | 36.76% | -172.12% | 21.91% | 9.17% | -11.38% | -51.31% | 36.99% | 13.8% | 43.78% |
Net Income | -12.27M | -32.1M | -43.17M | -27.12M | -26.84M | -37.9M | -27.33M | -24.72M | -33.52M |
Depreciation & Amortization | 1.89M | 2.94M | 3.42M | 3.33M | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
Stock-Based Compensation | 943K | 1.01M | 872K | 1.29M | 1.22M | 867K | 665K | 1.73M | 0 |
Deferred Taxes | -14K | 0 | 6.29M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -25K | -97K | 1K | 299K | -325K | -429K | 421K | 286K | 12.96M |
Working Capital Changes | -1M | -291K | 10.29M | 1.95M | 360K | -1.56M | -2.12M | -3.86M | 939K |
Change in Receivables | -1.43M | 717K | 12.19M | 2.85M | -1.38M | -5.12M | -1.68M | -3.23M | 2.32M |
Change in Inventory | -440K | 112K | 615K | -1.13M | 413K | -416K | -452K | -1.09M | -1.93M |
Change in Payables | 867K | -1.12M | -2.51M | 0 | 0 | 0 | 0 | 0 | 550K |
Cash from Investing | -6.05M | -1.34M | -73K | -537K | -885K | -29.04M | -3.93M | -1.64M | -20.06M |
Capital Expenditures | -4.86M | -1.34M | -73K | -537K | -896K | -2.79M | -2.75M | -1.19M | -1.16M |
CapEx % of Revenue | 12% | 4.75% | 0.62% | 2.91% | 4.03% | 7.53% | 3.91% | 1.32% | 1.07% |
Acquisitions | -1.1M | 0 | 0 | 0 | 0 | -25M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -88K | -912K | 0 | 0 | 11K | -1.25M | -1.18M | -448K | -18.9M |
Cash from Financing | 573K | 41.67M | 17.96M | 14.29M | 66.5M | 20.72M | 32.28M | 44.6M | 12.7M |
Debt Issued (Net) | 346K | -358K | 8.71M | 1.49M | -1.06M | 22.13M | -3.27M | 11.59M | 23.93M |
Equity Issued (Net) | 0 | 42.42M | 9.58M | 13.88M | 68.57M | 0 | 39.6M | 40.74M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 227K | -393K | -324K | -1.07M | -1.01M | -1.41M | -4.05M | -7.73M | -11.23M |
Net Change in Cash | -14.04M▲ 0% | 9.38M▲ 166.8% | -4.15M▼ 144.3% | -6.1M▼ 46.8% | 42.55M▲ 797.8% | -42.99M▼ 201.1% | 6.88M▲ 116.0% | 24.42M▲ 255.1% | -17.77M▼ 172.8% |
Free Cash Flow | -15.35M▲ 0% | -29.89M▼ 94.7% | -22.36M▲ 25.2% | -20.78M▲ 7.1% | -23.44M▼ 12.8% | -38.28M▼ 63.3% | -26.52M▲ 30.7% | -20.69M▲ 22.0% | -11.57M▲ 44.1% |
FCF Margin % | -37.89% | -105.47% | -189.75% | -112.57% | -105.42% | -103.31% | -37.78% | -22.98% | -10.73% |
FCF Growth % | 28.51% | -94.72% | 25.18% | 7.07% | -12.81% | -63.29% | 30.73% | 21.98% | 44.06% |
FCF per Share | -3.08 | -5.19 | -3.57 | -2.50 | -1.92 | -2.41 | -1.02 | -0.43 | -0.23 |
FCF Conversion (FCF/Net Income) | 0.85x | 0.88x | 0.52x | 0.71x | 0.78x | 0.77x | 0.50x | 0.49x | 0.31x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDXH Key Ratios
MDxHealth S.A. (MDXH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -27.16% | -25.52% | -67.84% | -119.99% | -224.16% | -109.96% | -156.7% | -521.7% | -345.31% | -2440.41% |
Return on Invested Capital (ROIC) | -51.57% | -36.55% | -89.09% | -184.4% | -281.69% | -414.04% | -151.35% | -68.66% | -68.42% | -28.14% |
Gross Margin | 66.17% | 74.81% | 58.88% | -1.22% | 43.58% | 47.5% | 51.87% | 62.58% | 61.23% | 59.74% |
Net Margin | -44.11% | -30.33% | -114.51% | -365.72% | -155.27% | -130.41% | -118.86% | -61.4% | -42.28% | -31.07% |
Debt / Equity | 0.01x | 0.02x | 0.01x | 0.56x | 2.71x | 0.33x | 4.27x | 5.72x | 4.05x | - |
Interest Coverage | - | -101.65x | -395.23x | -83.64x | -17.70x | -14.47x | -15.06x | -6.47x | -3.94x | -1.27x |
FCF Conversion | 1.26x | 0.85x | 0.88x | 0.52x | 0.71x | 0.78x | 0.77x | 0.50x | 0.49x | 0.31x |
Revenue Growth | 70.99% | 35.63% | -30.04% | -58.41% | 56.64% | 20.47% | 66.62% | 89.43% | 28.29% | 19.8% |
Related:MDXH Dividend History·MDXH Revenue History·MDXH Price History·MDXH P/E History·MDXH Financial Ratios·MDXH Institutional Holders
MDXH Frequently Asked Questions
MDxHealth S.A. (MDXH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MDxHealth S.A. (MDXH) reported $171.3M in revenue for fiscal year 2025. This represents a 32472% increase from $0.5M in 2004.
MDxHealth S.A. (MDXH) grew revenue by 19.8% over the past year. This is strong growth.
MDxHealth S.A. (MDXH) reported a net loss of $64.2M for fiscal year 2025.
Dividend & Returns
MDxHealth S.A. (MDXH) has a return on equity (ROE) of -2440.4%. Negative ROE indicates the company is unprofitable.
MDxHealth S.A. (MDXH) had negative free cash flow of $22.3M in fiscal year 2025, likely due to heavy capital investments.